A retatrutide protocol circulating online has a real paper to borrow from
That makes the borrowing more convincing than usual. It also makes it more misleading, because the numbers are genuine and everything that made them work is not in the copy.
The second half belongs here rather than further down. Retatrutide is approved in no market, so no clinician can prescribe it and no pharmacy can dispense it. A plan for it is therefore never a prescription, however closely it is modelled on a trial that genuinely exists.
Most plans in this market cite animal studies or nothing at all. This one can point at a randomised, placebo controlled trial in adults, published in a serious journal, and the person who wrote the plan is not making anything up when they quote it.
Notice what that does to a reader. The usual sceptical move, checking whether the cited research exists, passes. The numbers check out. The journal is real. The effect was large. Everything a careful person would verify comes back clean, and the plan looks stronger than any of its neighbours in the same market.
The question that separates them is not whether the source is real. It is what the source was attached to.
What the trial fixed in writing before anyone was enrolled
A trial protocol is written first, registered, and reviewed by an ethics committee before a single participant is approached. It settles a specific list of things in advance.
Who may take part, and who may not. What the primary outcome is, so that success cannot be redefined afterwards. How participants are assigned to groups, and who is kept unaware of the assignment. The exact schedule of amounts and how it may be adjusted. What events must be reported, to whom, and how quickly. The circumstances under which an individual is withdrawn or the whole study is halted. What statistical analysis will be run, decided before the data exists. And an obligation to report the results whichever way they come out.
Every item on that list constrains the people running the study. That is the point of the document. It exists to stop them from finding what they hoped to find.
What each document promises, and to whom
The last row is not a technicality. It explains why every row above it exists.
| The promise | Registered trial protocol | Plan sold or shared online |
|---|---|---|
| Written before anyone is exposed | Required | Written to describe a purchase |
| Reviewed by an independent ethics committee | Required | No |
| Screens out people the drug could harm | Required, by trained staff | The reader screens themselves |
| Uses a product of verified identity and strength | The manufacturer's | An unverified vial |
| Someone with authority to stop | Investigator and monitoring board | Nobody |
| Adverse events must be reported | Required, on a deadline | Nowhere to report them |
| Results published either way | Expected | Nothing is recorded |
| Who carries the risk | The sponsor and the site | You |
The people who never made it into the trial
The published result describes what happened to people who were allowed in. It says nothing about the people who were not, and a plan copied from it carries no memory of them.
Trials of this kind exclude participants with particular conditions, particular histories, particular medications and particular test results, and each exclusion is there because somebody judged the risk unacceptable or the interpretation impossible. Those people did not appear in the trial. They do appear in the online market, because nothing stops them.
A person who would have been screened out is in the worst position available. They have a plan built from a population they were deliberately kept out of, no clinician who has looked at the reason they were kept out, and no monitoring that might catch the consequence.
Screening is invisible in a PDF
This is the part that documents cannot show, and it is worth dwelling on because it is easy to underestimate.
Screening for a trial is not a form. It is history taking, medication review, laboratory work and a clinician making a judgement, and its output is mostly the absence of something: the person who was never enrolled, the participant whose amount was held back, the individual withdrawn quietly in week nine.
None of that appears in the published paper except as a line in a flow diagram, and none of it appears in a copied plan at all. What a reader sees is the schedule that the surviving, screened, monitored population followed. The filtering that produced them is the invisible half of the result, and it is the half being discarded.
The provider who cannot legally be your prescriber
Some plans arrive with a clinician's name on them, which raises the question of what that name adds.
It adds real things. A licensed clinician can take a history, review your medications, and refuse. They can recognise that a symptom you mentioned in passing needs investigating. They are accountable to a regulator for their conduct and they carry insurance.
It does not add a prescription, because this compound has no marketing authorisation in any market. There is nothing to prescribe against, no pharmacy that can dispense it, and no legitimate supply chain that ends at their door. A clinician associated with a plan for this compound is not writing a prescription in any jurisdiction, whatever the paperwork resembles.
That combination is the specific hazard. A professional setting implies process. A citation to a New England Journal paper implies evidence. Put together, a reader constructs a supervised medical treatment from two accurate components, and nobody involved has to say a single false sentence.
The sentence an honest plan would have to include
Try writing the paragraph a plan would have to contain to be straight with its reader, and notice why it is never there.
It would say that the numbers below are from a Phase 2 trial, reported as trial amounts, and are not a recommendation. That the trial used a verified pharmaceutical product and you will not be using one. That participants were screened and monitored and you will not be. That the trial ran 48 weeks and says nothing about longer, or about what happens when you stop. That gastrointestinal effects were the most common problem and are dose related. That a Phase 2 trial of that size and length cannot identify uncommon or delayed harms, so nobody can tell you the full risk picture yet. That nothing that happens to you will be recorded anywhere. And that approved medicines in the same class exist and can be lawfully prescribed today.
A plan containing that paragraph would be honest, and it would sell very badly. That is the whole reason the paragraph is missing.
The forty eight weeks nobody copies
One detail gets dropped from every circulating plan, and it is the one that shapes the decision most.
The trial ran for 48 weeks and reported what happened during them. It did not report what happens in year three, and it could not, because it had not got there. It also did not report what happens after somebody stops, and for this class of medicine the established pattern after discontinuation is that weight returns. Nothing in the published Phase 2 result suggests this compound is exempt from that.
A plan sold as a course therefore has a hole in it exactly where the reader's real question sits. Someone considering this is not asking what a year looks like. They are asking what their life looks like afterwards, and the honest answer is that for approved medicines in this class the answer has generally been continued treatment, which for an unapproved compound means indefinite reliance on a grey market supply with no guarantee it will still exist.
A plan that ends at week 48 with no discussion of what follows is not incomplete by oversight. The part it leaves out is the part that would make a reader think hardest.